Evidence map›Paper›PMID 25869390›Full record

ReviewThe American journal of gastroenterology2015

BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia.

Cathy Bennett, Paul Moayyedi, Douglas A Corley, John DeCaestecker, Yngve Falck-Ytter, Gary Falk, Nimish Vakil, Scott Sanders, Michael Vieth, John Inadomi and 43 more

Erratum issuedOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The American journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 51 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 2 pooled it
19.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 168 citations in OpenAlex.

  1. Pooled it
  2. Guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020
    Guideline
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Diagnosis and Management of Barrett's Esophagus.Journal of clinical medicine · 2023
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Molecular characterization of Barrett's esophagus at single-cell resolution.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

53 authors at 20 institutions in 9 countries.

Cathy BennettCentre for Technology Enabled Health Research, Coventry University, Coventry, UK.
Paul MoayyediMcMaster University, Hamilton, Ontario, Canada.
Douglas A CorleyKaiser Permanente, Oakland, California, USA.
John DeCaesteckerLeicester General Hospital, Leicester, UK.
Yngve Falck-YtterCase Western Reserve University School of Medicine, Case and VA Medical Center Cleveland, Cleveland, Ohio, USA.
Gary FalkUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Nimish VakilUniversity of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Scott SandersNHS Foundation Trust, Warwick, UK.
Michael ViethKlinikum Bayreuth, Bayreuth, Germany.
John InadomiUniversity of Washington School of Medicine, Seattle, Washington, USA.
David AldulaimiWorcestershire Acute Hospitals NHS Trust, Redditch, UK.
Khek-Yu HoNational University Health System, Singapore, Singapore.
Robert OdzeBrigham and Women's Hospital, Boston, Massachusetts, USA.
Stephen J MeltzerJohns Hopkins School of Medicine, Baltimore, Maryland, USA.
Eamonn QuigleyWeill Cornell Medical College and Houston Methodist Hospital, Houston, Texas, USA.
Stuart GittensECD Solutions, Columbus, Ohio, USA.
Peter WatsonQueen's University, Belfast, UK.
Giovanni ZaninottoImperial College, St Mary's Hospital, London, UK.
Prasad G IyerMayo Clinic, Rochester, Minnesota, USA.
Leo AlexandreNorwich Medical School, University of East Anglia, Norwich, UK.
Yeng AngUniversity of Manchester, Manchester, UK.
James CallaghanDepartment of Gastroenterology, University Hospital Southampton, Southampton, UK.
Rebecca HarrisonLeicester General Hospital, Leicester, UK.
Rajvinder SinghLyell McEwin Hospital/University of Adelaide, Adelaide, South Australia, Australia.
Pradeep BhandariQueen Alexandra Hospital, Portsmouth, UK.
Raf BisschopsUniversity Hospitals Leuven, Leuven, Belgium.
Bita GeramizadehDepartment of Pathology, Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Philip KayeNottingham University Hospitals NHS Trust, Nottingham, UK.
Sheila KrishnadathGastrointestinal Oncology Research Group, AMC, Amsterdam, The Netherlands.
M Brian FennertyOregon Health and Science University, Portland, Oregon, USA.
Hendrik MannerDepartment of Gastroenterology HSK Wiesbaden, Wiesbaden, Germany.
Katie S NasonUniversity of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Oliver PechKrankenhaus Barmherzige Brueder, Regensburg, Germany.
Vani KondaUniversity of Chicago, Chicago, Illinois, USA.
Krish RagunathQueens Medical Centre, University of Nottingham, Nottingham, UK.
Imdadur RahmanUniversity Hospital Southampton, Southampton, UK.
Yvonne RomeroMayo Clinic, Rochester, Minnesota, USA.
Richard SamplinerUniversity of Arizona Cancer Center, Tucson, Arizona, USA.
Peter D SiersemaUniversity Medical Center Utrecht, Utrecht, The Netherlands.
Jan TackUniversity of Leuven, Leuven, Belgium.
Tony C K ThamUlster Hospital, Belfast, Northern Ireland, UK.
Nigel TrudgillSandwell and West Birmingham Hospitals NHS Trust, West Bromwich, UK.
David S WeinbergFox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Jean WangWashington University School of Medicine, Saint Louis, Missouri, USA.
Kenneth WangMayo Clinic, Rochester, Minnesota, USA.
Jennie Y Y WongYong Loo Lin School of Medicine, National University of Singapore, Singapore.
Stephen AttwoodDurham University, Durham, UK.
Peter MalfertheinerOtto-Von-Guericke-Universität Magdeburg, Magdeburg, Germany.
David MacDonaldUniversity of British Columbia, Vancouver, British Columbia, Canada.
Hugh BarrGloucestershire Royal Hospital, Gloucester, UK.
Mark K FergusonThe University of Chicago Medicine, Chicago, Illinois, USA.
Janusz JankowskiUniversity Hospitals Coventry and Warwickshire and University of Warwick, Coventry, UK.
BOB CAT Consortium
Leicester General Hospital · GBCoventry University · GBKaiser Permanente · USSouth Warwickshire NHS Foundation Trust · GBAbbott (Japan) · JPBayreuth Medical Center · DEEisai (Japan) · JPMcMaster University · CAOlympus (United States) · USUniversity of Wisconsin–Madison · USUniversity School · USAstellas Pharma (United States) · USAstraZeneca (United Kingdom) · GBBrigham and Women's Hospital · USCase Western Reserve University · USFox Chase Cancer Center · USFujifilm (Japan) · JPNational University Health System · SGOlympus (Japan) · JPQueen Alexandra Hospital · GB

Funding

Barriers to Early Detection of Esophageal AdenocarcinomaK07CA151613 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NASON, KATIE S · 2011 to 2015
$818k
Department of Health DRF-2013-06-115NCI NIH HHS K07 CA151613NCI NIH HHS K07CA511613NCI NIH HHS L30 CA179766
6 · The paper itself

Abstract

objectivesBarrett's esophagus (BE) is a common premalignant lesion for which surveillance is recommended. This strategy is limited by considerable variations in clinical practice. We conducted an international, multidisciplinary, systematic search and evidence-based review of BE and provided consensus recommendations for clinical use in patients with nondysplastic, indefinite, and low-grade dysplasia (LGD).

methodsWe defined the scope, proposed statements, and searched electronic databases, yielding 20,558 publications that were screened, selected online, and formed the evidence base. We used a Delphi consensus process, with an 80% agreement threshold, using GRADE (Grading of Recommendations Assessment, Development and Evaluation) to categorize the quality of evidence and strength of recommendations.

resultsIn total, 80% of respondents agreed with 55 of 127 statements in the final voting rounds. Population endoscopic screening is not recommended and screening should target only very high-risk cases of males aged over 60 years with chronic uncontrolled reflux. A new international definition of BE was agreed upon. For any degree of dysplasia, at least two specialist gastrointestinal (GI) pathologists are required. Risk factors for cancer include male gender, length of BE, and central obesity. Endoscopic resection should be used for visible, nodular areas. Surveillance is not recommended for <5 years of life expectancy. Management strategies for indefinite dysplasia (IND) and LGD were identified, including a de-escalation strategy for lower-risk patients and escalation to intervention with follow-up for higher-risk patients.

conclusionsIn this uniquely large consensus process in gastroenterology, we made key clinical recommendations for the escalation/de-escalation of BE in clinical practice. We made strong recommendations for the prioritization of future research.

Indexed as

Delphi TechniqueAblation TechniquesAge FactorsBarrett EsophagusBiomarkers, TumorBiopsyConsensus Statements as TopicDNA MethylationEsophageal NeoplasmsEsophagoscopyEsophagusHumansPrecancerous ConditionsRisk FactorsSex FactorsWatchful WaitingBiomarkers, Tumor

Identifiers

PMID25869390
PMCPMC4436697
OpenAlexW1972443519

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.